The identification of the Metab-GS along with the regulation of tumor suppressor metabolic hubs via DNA hypermethylation and the regulation of oncogenic metabolic hubs by the USF2-NuRD complex offers new insights into the mechanisms driving tumor aggressiveness and poor clinical outcomes in bladder cancer. The gene discussed is USF2; the disease is urinary bladder carcinoma.